Literature DB >> 18200364

[Concordance between clinical and pathological staging in patients with stages I or II non-small cell lung cancer subjected to surgical treatment].

Pedro Augusto Reck Dos Santos1, Rodrigo Sponchiado da Rocha, Maurício Pipkin, Marner Lopes da Silveira, Marcelo Cypel, Jayme Oliveira Rios, José Antonio Lopes de Figueiredo Pinto.   

Abstract

OBJECTIVE: To compare clinical and pathological staging in patients with non-small cell lung cancer submitted to surgical treatment, as well as to identify the causes of discordance.
METHODS: Data related to patients treated at the Department of Thoracic Surgery of the Pontifical Catholic University of Rio Grande do Sul São Lucas Hospital were analyzed retrospectively. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for clinical stages IA, IB, and IIB. The kappa index was used to determine the concordance between clinical and pathological staging.
RESULTS: Of the 92 patients studied, 33.7% were classified as clinical stage IA, 50% as IB, and 16.3% as IIB. The concordance between clinical and pathological staging was 67.5% for stage IA, 54.3% for IB, and 66.6% for IIB. The accuracy of the clinical staging was greater for stage IA, and a kappa of 0.74, in this case, confirmed a substantial association with pathological staging. The difficulty in evaluating nodal metastatic disease is responsible for the low concordance in patients with clinical stage IB.
CONCLUSIONS: The concordance between clinical and pathological staging is low, and patients are frequently understaged (in the present study, only one case was overstaged). Strategies are necessary to improve clinical staging and, consequently, the treatment and prognosis of patients with non-small cell lung cancer.

Entities:  

Mesh:

Year:  2007        PMID: 18200364     DOI: 10.1590/s1806-37132007000600007

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  1 in total

1.  Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.

Authors:  Chen-Ping Hsieh; Ming-Ju Hsieh; Ching-Feng Wu; Jui-Ying Fu; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.